Dalrada Financial Corp.'s Genefic, Inc. subsidiary reports significant revenue growth and success in specialty pharmacies due to a long-term strategy launched in 2023.

Dalrada Financial Corp.'s Genefic, Inc. subsidiary CEO, Dan Riley, discusses impressive revenue growth and ongoing success in specialty pharmacies. This success is a result of a long-term strategy launched in October 2023, contributing to traction within Genefic's pharmacy and laboratory division, which includes two licensed diagnostic labs, a 50-state licensed specialty pharmacy, and a recently-acquired infusion pharmacy.